°Ç¼±¼º °üÀý¿° ½ÃÀå : KOL ÀλçÀÌÆ®
Psoriatic Arthritis - KOL Insight
»óǰÄÚµå : 1487713
¸®¼­Ä¡»ç : FirstWord Group
¹ßÇàÀÏ : 2024³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 39,950 £Ü 57,803,000
Multi User License (PDF) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. PDF ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ °Ç¼±¼º °üÀý¿°(PsA) ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ¾ÈÀü¼º°ú À¯È¿¼ºÀÌ Áõ¸íµÈ Ç×TNF Á¦Á¦ÀÇ Áö¼ÓÀû ¿ìÀ§¼ººÎÅÍ ´ÏÄ¡ Ä¡·áÁ¦·Î¼­ BimzelxÀÇ °¡´É¼º, ÇǺΠÁõ»ó °ü¸®¿¡¼­ ½ºÄ«À̸®Áö/Æ®·½ÇǾÆÀÇ ¿ì¼öÇÑ À¯È¿¼º±îÁö ÇöÀç ¹× »õ·Î¿î Ä¡·á¹ý¿¡ ´ëÇØ °ËÅäÇϰí, ¿À´Ã³¯ PsA °ü¸®ÀÇ ÀÓ»ó °áÁ¤À» Çü¼ºÇϰí ÀÖ´Â Àü·«Àû ¼±È£µµ ¹× ½Çõ¿¡ °üÇÑ ±ÍÁßÇÑ ÀλçÀÌÆ®À» Á¦°øÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

°³¿ä

°Ç¼±¼º °üÀý¿°ÀÇ ÇöÀç ¹× ÇâÈÄ Ä¡·á ¾Ë°í¸®Áò

Á¶»ç ¸ñÀû

½ÂÀÎ ¾àÁ¦

ÆÄÀÌÇÁ¶óÀÎ ¾àÁ¦

°Ç¼±¼º °üÀý¿° Ä¡·áÀÇ ÇâÈÄ µ¿Çâ°ú °¡´É¼º

ºÎ·Ï

KOL º¸°í¼­

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Insights from leading KOLs on the evolving landscape of psoriatic arthritis (PsA) treatment. From the continued dominance of anti-TNFs due to their proven safety and efficacy to Bimzelx's potential as a niche treatment and Skyrizi/Tremfya's superior efficacy in managing skin symptoms, this report examines current and emerging therapies providing valuable insights into the strategic preferences and practices that are shaping clinical decisions in PsA management today.

Table of Contents

Executive summary

Current and future treatment algorithm for psoriatic arthritis

Research objectives

Approved drugs (105)

Pipeline drugs

Future trends and opportunities in psoriatic arthritis treatment

Appendix

KOL Bulletins

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â